Results 51 to 60 of about 469,402 (307)

Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes [PDF]

open access: yes, 2013
Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes.
Blad C. C.   +18 more
core   +1 more source

Personalizing the Pediatric Hematology/Oncology Fellowship: Adapting Training for the Next Generation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT The pediatric hematology‐oncology fellowship training curriculum has not substantially changed since its inception. The first year of training is clinically focused, and the second and third years are devoted to scholarship. However, this current structure leaves many fellows less competitive in the current job market, resulting in ...
Scott C. Borinstein   +3 more
wiley   +1 more source

POTENCY TEST OF COMMERCIALLY AVAILABLE INACTIVATED NEWCASTLE DISEASE VACCINES IN SERBIA

open access: yesArchives of Veterinary Medicine, 2015
In order to evaluate the efficacy of inactivated oil-emulsion Newcastle disease vaccine (commercially available on market in Serbia) we carried out the potency test in chickens, using hemagglutination inhibition (HI) test for detection of antibodies.
Marina Žekić Stošić   +5 more
doaj   +1 more source

A comparison of the results from intra-pleural and intra-peritoneal studies with those from inhalation and intratracheal tests for the assessment of pulmonary responses to inhalable dusts and fibres. [PDF]

open access: yes, 2016
The aim of this paper is to compare results from inhalation studies with those from intraperitoneal and intrapleural tests, where available, for a number of fibrous and particulate test materials.
Bevan, Ruth   +2 more
core   +2 more sources

Psychosocial Outcomes in Patients With Endocrine Tumor Syndromes: A Systematic Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction The combination of disease manifestations, the familial burden, and varying penetrance of endocrine tumor syndromes (ETSs) is unique. This review aimed to portray and summarize available data on psychosocial outcomes in patients with ETSs and explore gaps and opportunities for future research and care.
Daniël Zwerus   +6 more
wiley   +1 more source

Establishment of an in vivo potency assay for the recombinant hepatit is B surface antigen in monovalent and combined vaccines

open access: yesVacciMonitor, 2014
In this paper the development of potency assay in animals (mice) was made, with the objective of demonstrating the immunogenic power of the recombinant Hepatitis B surface antigen in monovalent and combined vaccines, produced at the Center of Genetic ...
Mabel Izquierdo-López   +9 more
doaj  

Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products

open access: yesJournal of Translational Medicine
Cell therapy product (CTP) developers face the significant challenge of developing appropriate potency tests for their CTPs. A review of the known potency tests used for the 31 United States Food and Drug Administration-approved CTPs (US FDA) can guide ...
Carl G. Simon   +13 more
doaj   +1 more source

Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes [PDF]

open access: yes, 2018
The realisation of the therapeutic potential of targeting the M1 muscarinic acetylcholine receptor (M1 mAChR) for the treatment of cognitive decline in Alzheimer's disease has prompted the discovery of M1 mAChR ligands showing efficacy in alleviating ...
Bradley, Sophie J.   +14 more
core   +1 more source

Nutritional and Behavioral Intervention for Long‐Term Childhood Acute Leukemia Survivors With Metabolic Syndrome

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Metabolic syndrome (MetS) is a common complication in survivors of childhood acute lymphoblastic and myeloid leukemia (AL), and a major risk factor for premature cardiovascular disease, type‐2‐diabetes, and metabolic dysfunction‐associated steatotic liver disease (MASLD).
Visentin Sandrine   +10 more
wiley   +1 more source

Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. [PDF]

open access: yes, 2019
Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB) treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB patients.
Alvarez-Cabrera, Nadine   +16 more
core   +2 more sources

Home - About - Disclaimer - Privacy